The global encapsulated lactic acid market is projected to grow from USD 1.45 billion in 2026 to USD 2.01 billion by 2031, with a CAGR of 6.72%. Growth is driven by rising demand in nutraceuticals, probiotics, and functional foods, with liquid formats showing the fastest growth at 8.02% CAGR. However, high encapsulation costs and manufacturing complexity remain key challenges. North America leads with 40.21% market share, while Asia-Pacific is the fastest-growing region at 7.62% CAGR.

The global encapsulated essential oils for feed market is projected to grow from $1.18 billion in 2026 to $1.67 billion by 2030, with a CAGR of 9.1%. Key growth drivers include rising demand for antibiotic-free livestock production, natural gut-health additives, controlled-release encapsulation technologies, and aquaculture-specific feeds, particularly in Asia-Pacific regions.

Balchem Corporation announced its participation in the CJS Securities 26th Annual New Ideas Summer Conference on July 9, 2026, with key executives including CEO Ted Harris, CFO Martin Bengtsson, and Senior Director of Investor Relations Allison Baurichter attending the event.

Balchem Corporation announced its participation in the BNP Paribas Exane Consumer Ingredients & Chemicals Conference on March 11, 2026, with senior executives including CEO Ted Harris, CFO Martin Bengtsson, and Senior Director of Investor Relations Allison Baurichter attending. The company also plans to participate in the JP Morgan Consumer Ingredients Forum on March 10, 2026.

Balchem Corporation announced a conference call scheduled for February 20, 2026, at 11:00 AM ET to discuss fourth quarter and full year 2025 financial results. The call will be hosted by CEO Ted Harris and CFO Martin Bengtsson, with results to be published prior to market opening. The company also noted attendance at the CJS Securities 26th Annual New Ideas for the New Year Virtual Conference on January 14, 2026.

The European Union has implemented anti-dumping duties of 90.0-115.9% on choline chloride imports from China, effective for five years. EU producers Eastman and Balchem welcome the decision, citing protection of European jobs, supply chain security, and fair trade practices. The EU also clarified customs origin rules to prevent circumvention through transshipment via third countries.

Balchem director David B. Fischer sold 8,000 shares for $1.2 million, reducing his direct holdings by 50%. The sale occurred a week before the company announced a 10.3% dividend increase and reported record quarterly sales growth.

Balchem Corporation declared a quarterly dividend of $0.96 per share, representing a 10.3% increase from the previous year. This marks the company's seventeenth consecutive annual dividend increase, reflecting strong financial performance and confidence in long-term strategies.

Balchem Corporation will present at the H.C. Wainwright 27th Annual Global Investment Conference on September 9, 2025, with key executives including Ted Harris, Martin Bengtsson, and Allison Baurichter.

Balchem reported strong Q2 2025 financial performance, with 9.1% revenue growth to $255.5 million, non-GAAP EPS of $1.27, and strategic investments in micro-encapsulation technologies. All business segments showed growth, and the company benefited from favorable EU trade regulations.

Balchem Corporation will host a conference call on July 31, 2025, at 11:00 AM ET to review second quarter 2025 financial results, with CEO Ted Harris and CFO Martin Bengtsson presenting.

The global magnesium supplements market is projected to grow from USD 4.37 billion in 2024 to USD 8.94 billion by 2034, with a 7.43% CAGR, driven by increasing health awareness, clean-label products, and personalized nutrition trends.